Nothing currently in dispute alters the fact that the industry groups agreed to a shift in the use of legal these terms which delivers a dramatic and probably irreversible expansion in the government's power to extract price reductions from companies with PBS-listed medicines. …
Why would it take these powers if it did not intend to use them?
September 28, 2022 Latest NewsBioPharmaComment
Latest Video
Georgia Forrest
New Stories
-
A 'fit for purpose' HTA system will be accompanied by a 'fit for purpose' cost recovery framework
December 19, 2025 - - Latest News -
Cleo Diagnostics raises funds to accelerate US launch and advance ovarian cancer screening
December 18, 2025 - - Australian Biotech -
Actinogen crosses key milestone as pivotal Alzheimer’s trial fully enrols
December 18, 2025 - - Australian Biotech -
Pharmac scraps plan to remove low-ranked medicines from options for funding list
December 18, 2025 - - Latest News -
PBAC reflects on a year shaped by major reviews and rising workload
December 18, 2025 - - Latest News -
Priceline moves to stabilise banner group as pressures force administrators
December 17, 2025 - - Latest News -
Rare Cancers Australia gearing up for 2026 Kosi Challenge with Pharma Cup up for grabs again
December 17, 2025 - - Latest News